Marker Therapeutics Files Q3 2024 10-Q

TL;DR

Marker Therapeutics filed its Q3 2024 10-Q. Financials and operations update.

AI Summary

Marker Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal business address is in Houston, Texas.

Why It Matters

This filing provides investors with the latest financial and operational updates for Marker Therapeutics, Inc., crucial for understanding the company's performance and outlook.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Marker Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 20240930 — End of Fiscal Period (The 10-Q covers financial results up to this date.)
• 20241114 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• Marker Therapeutics, Inc. (company) — Filer of the 10-Q
• TAPIMMUNE INC. (company) — Former name of Marker Therapeutics
• GENEMAX CORP (company) — Former name of Marker Therapeutics
• 20240930 (date) — End of the reporting period
• 20241114 (date) — Filing date
• Houston, TX (location) — Business and mailing address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar

Filing Documents

• mrkr-20240930x10q.htm (10-Q) — 1265KB
• mrkr-20240930xex31d1.htm (EX-31.1) — 12KB
• mrkr-20240930xex31d2.htm (EX-31.2) — 12KB
• mrkr-20240930xex32d1.htm (EX-32.1) — 6KB
• mrkr-20240930xex32d2.htm (EX-32.2) — 6KB
• mrkr-20240930x10q001.jpg (GRAPHIC) — 9KB
• mrkr-20240930x10q002.jpg (GRAPHIC) — 46KB
• mrkr-20240930x10q003.jpg (GRAPHIC) — 30KB
• 0001410578-24-001978.txt ( ) — 5468KB
• mrkr-20240930.xsd (EX-101.SCH) — 39KB
• mrkr-20240930_cal.xml (EX-101.CAL) — 32KB
• mrkr-20240930_def.xml (EX-101.DEF) — 164KB
• mrkr-20240930_lab.xml (EX-101.LAB) — 305KB
• mrkr-20240930_pre.xml (EX-101.PRE) — 253KB
• mrkr-20240930x10q_htm.xml (XML) — 775KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 2 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 29 Item 4.

Controls and Procedures

Controls and Procedures. 29

– OTHER INFORMATION

PART II – OTHER INFORMATION 30 Item 1. Legal Proceedings. 30 Item 1A. Risk Factors. 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 30 Item 3. Defaults Upon Senior Securities. 30 Item 4. Mine Safety Disclosure. 30 Item 5. Other Information. 30 Item 6. Exhibits. 31

Signatures

Signatures 33 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statement s

Item 1. Financial Statement s MARKER THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) September 30, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 8,999,664 $ 15,111,450 Prepaid expenses and deposits 1,166,274 988,126 Other receivables 744,410 1,027,815 Total current assets 10,910,348 17,127,391 Total assets $ 10,910,348 $ 17,127,391 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 2,557,335 $ 1,745,193 Related party payable 903,438 1,329,655 Total current liabilities 3,460,773 3,074,848 Total liabilities 3,460,773 3,074,848 Stockholders' equity: Preferred stock, $ 0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively — — Common stock, $ 0.001 par value, 30 million shares authorized, 8.9 million shares issued and outstanding as of September 30, 2024 and December 31, 2023 (see Note 9) 8,923 8,891 Additional paid-in capital 450,620,206 450,329,515 Accumulated deficit ( 443,179,554 ) ( 436,285,863 ) Total stockholders' equity 7,449,575 14,052,543 Total liabilities and stockholders' equity $ 10,910,348 $ 17,127,391 See accompanying notes to these unaudited condensed consolidated financial statements. 1 Table of Contents MARKER THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months Ended For the Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Revenues: Grant income $ 1,926,020 $ 257,606 $ 4,339,317 $ 2,254,601 Total revenues 1,926,020 257,606 4,339,317 2,254,601 Operating expenses: Research and development 3,471,216 2,044,980 8,381,661 7,799,472 General and administrative 854,677 1,412,672 3,214,611 6,098,716 Total operating expenses 4,325,893 3,457,652

View Full Filing

View this 10-Q filing on SEC EDGAR